Validity of ICD-10-CM Codes Used to Identify Patients with Chronic Hepatitis B and C Virus Infection in Administrative Claims Data from the Taiwan National Health Insurance Outpatient Claims Dataset

References

• Wu CY, Chen YJ, Ho HJ, et al. Association between nucleoside analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection. JAMA. 2012;308(18):1906–1914. doi:10.1001/2012.jama.1197523162861
   PubMed Web of Science ®Google Scholar
• Tsan YT, Lee CH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol. 2012;30(6):623–630. doi:10.1200/JCO.2011.36.091722271485
   PubMed Web of Science ®Google Scholar
• Tsan YT, Lee CH, Ho WC, et al. Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection. J Clin Oncol. 2013;31(12):1514–1521. doi:10.1200/JCO.2012.44.683123509319
   PubMed Web of Science ®Google Scholar
• Hsu YC, Ho HJ, Wu MS, Lin JT, Wu CY. Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma. Hepatology. 2013;58(1):150–157. doi:10.1002/hep.2630023389758
   PubMed Web of Science ®Google Scholar
• Hsu YC, Lin JT, Ho HJ, et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology. 2014;59(4):1293–1302. doi:10.1002/hep.2689224122848
   PubMed Web of Science ®Google Scholar
• Chiang CJ, Yang YW, Chen JD, et al. Significant reduction in end-stage liver diseases burden through the national viral hepatitis therapy program in Taiwan. Hepatology. 2015;61(4):1154–1162. doi:10.1002/hep.2763025476749
   PubMed Web of Science ®Google Scholar
• Hsu YC, Ho HJ, Huang YT, et al. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut. 2015;64(3):495–503. doi:10.1136/gutjnl-2014-30816325398770
   PubMed Web of Science ®Google Scholar
• Yang YH, Chen WC, Tsan YT, et al. Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection. J Hepatol. 2015;63(5):1111–1117. doi:10.1016/j.jhep.2015.07.00626196278
   PubMed Web of Science ®Google Scholar
• Huang YW, Lee CL, Yang SS, et al. Statins reduce the risk of cirrhosis and its decompensation in chronic hepatitis B patients: a nationwide cohort study. Am J Gastroenterol. 2016;111(7):976–985. doi:10.1038/ajg.2016.17927166128
   PubMed Web of Science ®Google Scholar
• Lee TY, Lin JT, Zeng YS, et al. Association between nucleos(t)ide analog and tumor recurrence in hepatitis B virus-related hepatocellular carcinoma after radiofrequency ablation. Hepatology. 2016;63(5):1517–1527. doi:10.1002/hep.2826626426978
   PubMed Web of Science ®Google Scholar
• Chang FM, Wang YP, Lang HC, et al. Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: a population-based study. Hepatology. 2017;66(3):896–907. doi:10.1002/hep.2917228318053
   PubMed Web of Science ®Google Scholar
• Lee TY, Hsu YC, Tseng HC, et al. Association of daily aspirin therapy with risk of hepatocellular carcinoma in patients with chronic hepatitis B. JAMA Intern Med. 2019;179(5):633–640. doi:10.1001/jamainternmed.2018.834230882847
   PubMed Web of Science ®Google Scholar
• Chun DS, Lund JL, Stürmer T. Pharmacoepidemiology and drug safety’s special issue on validation studies. Pharmacoepidemiol Drug Saf. 2019;28(2):123–125. doi:10.1002/pds.469430714240
   PubMed Web of Science ®Google Scholar
• Koram N, Delgado M, Stark JH, Setoguchi S, de Luise C. Validation studies of claims data in the Asia-Pacific region: a comprehensive review. Pharmacoepidemiol Drug Saf. 2019;28(2):156–170. doi:10.1002/pds.461630022560
   PubMed Web of Science ®Google Scholar
• Kramer JR, Davila JA, Miller ED, et al. The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases. Aliment Pharmacol Ther. 2008;27(3):274–282. doi:10.1111/j.1365-2036.2007.03572.x17996017
   PubMed Web of Science ®Google Scholar
• Niu B, Forde KA, Goldberg DS. Coding algorithms for identifying patients with cirrhosis and hepatitis B or C virus using administrative data. Pharmacoepidemiol Drug Saf. 2015;24(1):107–111. doi:10.1002/pds.v24.125335773
   PubMed Web of Science ®Google Scholar
• Mahajan R, Moorman AC, Liu SJ, et al. Use of the international classification of diseases, 9th revision, coding in identifying chronic hepatitis B virus infection in health system data: implications for national surveillance. J Am Med Inform Assoc. 2013;20(3):441–445. doi:10.1136/amiajnl-2012-00155823462875
   PubMed Web of Science ®Google Scholar
• Abara WE, Moorman AC, Zhong Y, et al. The predictive value of international classification of disease codes for chronic hepatitis C virus infection surveillance: the utility and limitations of electronic health records. Popul Health Manag. 2018;21(2):110–115. doi:10.1089/pop.2017.0004
   Web of Science ®Google Scholar
• Hsing AW, Ioannidis JPA. Nationwide population science: lessons from the Taiwan national health insurance research database. JAMA Intern Med. 2015;175(9):1527–1529. doi:10.1001/jamainternmed.2015.354026192815
   PubMed Web of Science ®Google Scholar
• Lin LY, Warren-Gash C, Smeeth L, Chen PC. Data resource profile: the National Health Insurance Research Database (NHIRD). Epidemiol Health. 2018;40:e2018062. doi:10.4178/epih.e201806230727703
   PubMed Web of Science ®Google Scholar
• Taiwan Health Promotion Administration. Criteria for HBV and HCV tests in adult preventive health checkup. Available from https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=814&pid=4496. Accessed 8 30, 2019.
   Google Scholar
• Taiwan National Health Insurance Administration. Introduction of National Health Insurance MediCloud System. Available from https://www.nhi.gov.tw/Content_List.aspx?n=B5612D76EB95D83D&topn=CA428784F9ED78C9. Accessed 8 30, 2019.
   Google Scholar
• Taiwan National Health Insurance Administration. Guidelines for submission of results of laboratory tests and reports of examinations. Available from https://www.nhi.gov.tw/Content_List.aspx?n=264416706E2EF4DA&topn=D39E2B72B0BDFA15. Accessed 8 30, 2019.
   Google Scholar
• Taiwan National Health Insurance Administration. Claims format for contracted clinics and hospitals. Available from https://www.nhi.gov.tw/Content_List.aspx?n=AAA5E2B2776DD4CD&topn=D39E2B72B0BDFA15. Accessed 8 30, 2019.
   Google Scholar
• Altman D, Machin D, Bryant T, Gardner M. Statistics with Confidence: Confidence Intervals and Statistical Guidelines. 2nd ed. London: BMJ Books; 2000.
   Google Scholar
• Chen DS. Taiwan commits to eliminating hepatitis C in 2025. Lancet Inf Dis. 2019;19(5):466–467. doi:10.1016/S1473-3099(19)30170-7
   Web of Science ®Google Scholar
• Liu CH, Yu ML, Peng CY, et al. Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: the INITIATE study. J Formos Med Assoc. 2019;118(6):1014–1023. doi:10.1016/j.jfma.2018.10.02030448077
   PubMed Web of Science ®Google Scholar